Biotechnology News and Research

RSS

Informative session on TP-drug interactions

AAPS is pleased to present the workshop on Strategies to Address Therapeutic Protein Drug Interactions during Clinical Development. This event will feature a review of pre-clinical tools, test systems, and relevant documented Therapeutic Protein-drug interactions.

4 May 2010

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN N.V. today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010.

From QIAGEN Manchester Limited 4 May 2010

TB Alliance, AstraZeneca sign research collaboration agreement to develop drugs against tuberculosis

The Global Alliance for TB Drug Development and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis, including drug resistant strains of the disease.

4 May 2010

Baxter Healthcare's COLLEAGUE infusion pumps to be recalled

Baxter Healthcare Corporation today announced that it will recall COLLEAGUE infusion pumps from the U.S. market pursuant to an order under its existing June 2006 consent decree with the U.S. Food and Drug Administration (FDA). Baxter will work with the FDA to ensure that the recall process provides customers appropriate alternatives for supporting patients' needs.

4 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

Boost for biologics manufacturing in Australia

AusBiotech has welcomed the news that Australia’s first major contract manufacturing facility for biologic medicines has secured backing and is set to be built in Queensland by 2012.

3 May 2010

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.

3 May 2010

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chairman, president and chief executive officer, has been invited to participate in Retina International's annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010.

3 May 2010

BioTime acquires ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd.

3 May 2010

Spectros, Philips Electronics enter patent sale agreement covering multispectral pulse oximetry technology

Spectros announced today that it entered into a patent sale agreement with Koninklijke Philips Electronics N.V. ( PHG). Under this agreement, Philips purchased a patent related to technology for multispectral pulse oximetry, an approach first developed and patented by Spectros.

3 May 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.

From Santen Pharmaceutical Co., Ltd. 3 May 2010

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.

3 May 2010

Family Tree DNA announces launch of Family Finder DNA test

Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family members across all ancestral lines. The test utilizes Affymetrix' recently launched Axiom genotyping technology and the GeneTitan® System to confidently match a wide range of family relationships within five generations.

3 May 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).

3 May 2010

PolyTouch Medical files Premarket 510(k) application for PatchAssist laparoscopic mesh deployment device

PolyTouch Medical Ltd., a leading developer of laparoscopic hernia mesh placement technologies, today announced that it has filed a Premarket 510(k) Application with the US Food and Drug Administration for PatchAssist, an Innovative Laparoscopic Mesh Deployment and Placement Device that enables accurate mesh placement in laparoscopic ventral hernia repair potentially reducing procedure time by 30%-50%.

3 May 2010

Stimatix reports interim results from artificial sphincter trial for restoring bowel control in people with stoma

Stimatix GI, located in the Misgav Venture Accelerator, has reported encouraging interim results in its animal trials of the AOS-C1000 artificial sphincter, designed to provide stoma patients with a new means of bowel control.

3 May 2010

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.

3 May 2010

Sistemic announces availability new SistemRNA Technology

Sistemic today announced immediate availability new SistemRNA product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets.

3 May 2010

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.

3 May 2010

Watson Pharmaceuticals sued in connection with filing ANDA for generic equivalent of Trilipix

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with the filing of Watson's Abbreviated New Drug Application for choline fenofibrate delayed-release capsules in the 45 mg and 135 mg strengths.

3 May 2010

Biotechnology News and Research

Informative session on TP-drug interactions

QIAGEN reports 20% revenue growth in first quarter 2010

TB Alliance, AstraZeneca sign research collaboration agreement to develop drugs against tuberculosis

Baxter Healthcare's COLLEAGUE infusion pumps to be recalled

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Boost for biologics manufacturing in Australia

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

BioTime acquires ES Cell International

Spectros, Philips Electronics enter patent sale agreement covering multispectral pulse oximetry technology

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Family Tree DNA announces launch of Family Finder DNA test

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

PolyTouch Medical files Premarket 510(k) application for PatchAssist laparoscopic mesh deployment device

Stimatix reports interim results from artificial sphincter trial for restoring bowel control in people with stoma

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

Sistemic announces availability new SistemRNA Technology

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Watson Pharmaceuticals sued in connection with filing ANDA for generic equivalent of Trilipix

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News